Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 4, 2003, Pages 369-377

  Sirén, Vappu ^a   Kauhanen, Petteri ^b   Carpén, Olli ^a   Luther, Michael ^c   Lepäntalo, Mauri ^b   Vaheri, Antti ^a   Lassila, Riitta ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Plasminogen activator inhibitor 1; Thrombosis; Tissue type plasminogen activator; Urokinase; Vein graft

Indexed keywords

CD31 ANTIGEN; FIBRIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT OCCLUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBENDOTHELIUM; THROMBOCYTE; THROMBOSIS; VEIN GRAFT;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CONSTRICTION, PATHOLOGIC; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR; VEINS; VENOUS THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 0037832629     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200306000-00008     Document Type: Article

References (29)

1. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15:1667-1687.
2. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91:439-442.
3. Collen D. On the regulation of fibrinolysis. Thromb Haemost 1979; 43:77-89.
4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Prasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44:139-266.
5. Pöllätnen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57:273-328.
6. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89:6998-7002.
7. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13:1090-1100.
8. Lupu F, Heim A, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expressions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15:1444-1455.
9. Noda-Heiny H, Daugherty A, Burton ES. Augmented urokinase receptor expressions in atheroma. Arterioscler Thromb Vasc Biol 1995; 15:37-43.
10. Falkenberg M, Tjärnström J, Örtenwall P, Olausson M, Risberg B. Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels. Thromb Haemost 1996; 75:933-938.
11. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996; 16:1373-1382.
12. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99:200-208.
13. Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81:829-839.
14. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation 1997; 96:3180-3191.
15. Arnman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994; 76:487-499.
16. Peltonen S, Lassila R, Lepäntalo M. Increased circulating plasminogen activator inhibitor-1 in patients with patent femorodistal venous bypass. Thromb Res 1996; 82:369-377.
17. Rifón J, Páramo JA, Panizo C, Montes R, Rocha E. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol 1997; 99:262-267.
18. Kauhanen P, Sirén V, Carpėn O, Vaheri A, Lepäntalo M, Lassila R. Plasminogen activator inhibitor-1 in neointima of vein grafts. Its role in reduced fibrinolytic potential and graft failure. Circulation 1997; 96:1783-1789.
19. Okada SS, Golden MA, Ragnunath PN, Tomaszewski JE, David ML, Kuo A, et al. Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. Thromb Haemost 1998; 80:140-147.
20. Ruggeri ZM: Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78:611-616.
21. Jeremy JY, Mehta D, Bryan AJ, Lewis D, Angelini GD. Platelets and saphenous vein graft failure following coronary artery bypass surgery. Platelets 1997; 8:295-309.
22. Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci USA 1984; 81:4727-4731.
23. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, et al. Plasminogen activator inhibitor type 1: reactive center and aminoterminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209:213-218.
24. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van der Oord JJ, De Mol M, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II Effects on haemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92:2756-2760.
25. Lenich C, Liu JN, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90:3579-3586.
26. Park S, Harker L, Ulla MM, Levin EG. Demonstration of single chain urokinase-type plasminogen activator in platelet membrane. Blood 1989; 73:1421-1425.
27. Erickson LA, Ginsberg MH, Loskutoff DL. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74:1465-1472.
28. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34:45-68.
29. Golledge J. Vein grafts: haemodynamic forces on the endothelium - a review. Eur J Vasc Endovasc Surg 1997; 14:333-343.